Published in Toxicology on October 07, 2007
PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal (2010) 2.08
Molecular mechanisms of alcoholic fatty liver. Alcohol Clin Exp Res (2008) 1.59
Transcriptome Analysis Reveals Regulation of Gene Expression for Lipid Catabolism in Young Broilers by Butyrate Glycerides. PLoS One (2016) 1.38
PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr (2011) 1.34
Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. J Lipid Res (2010) 1.30
Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci (2010) 1.29
Maternal high fat diet during pregnancy and lactation alters hepatic expression of insulin like growth factor-2 and key microRNAs in the adult offspring. BMC Genomics (2009) 1.29
The Role of PPARs in Cancer. PPAR Res (2008) 1.26
Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity. Hepatology (2012) 1.09
Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress. Free Radic Biol Med (2009) 1.08
Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol (2010) 1.06
PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res (2012) 1.03
The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem (2010) 1.03
Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics (2010) 1.01
Differential network analysis for the identification of condition-specific pathway activity and regulation. Bioinformatics (2013) 0.99
ATM functions at the peroxisome to induce pexophagy in response to ROS. Nat Cell Biol (2015) 0.96
A Pex7 hypomorphic mouse model for plasmalogen deficiency affecting the lens and skeleton. Mol Genet Metab (2009) 0.96
A metabolomics investigation of non-genotoxic carcinogenicity in the rat. J Proteome Res (2013) 0.96
Cyclic AMP-dependent protein kinase signaling modulates pregnane x receptor activity in a species-specific manner. J Biol Chem (2009) 0.95
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol (2011) 0.95
Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer. Genome Med (2012) 0.93
Peroxisome proliferator-activated receptors for hypertension. World J Cardiol (2014) 0.92
Role of Myc in hepatocellular proliferation and hepatocarcinogenesis. J Hepatol (2013) 0.92
Time-course comparison of xenobiotic activators of CAR and PPARalpha in mouse liver. Toxicol Appl Pharmacol (2008) 0.90
PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents. PPAR Res (2008) 0.90
Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. PPAR Res (2015) 0.87
Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers. Xenobiotica (2009) 0.87
PPARα activation can help prevent and treat non-small cell lung cancer. Cancer Res (2013) 0.87
Divergence between human and murine peroxisome proliferator-activated receptor alpha ligand specificities. J Lipid Res (2013) 0.86
Mechanisms of peroxisome proliferator-induced DNA hypomethylation in rat liver. Mutat Res (2008) 0.86
Role of PPARα in Hepatic Carbohydrate Metabolism. PPAR Res (2010) 0.86
Nuclear hormone receptors in diabetic nephropathy. Nat Rev Nephrol (2010) 0.86
Fibrates and cholestasis. Hepatology (2015) 0.86
Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. PPAR Res (2008) 0.85
Gene Expression Profiling in Wild-Type and PPARα-Null Mice Exposed to Perfluorooctane Sulfonate Reveals PPARα-Independent Effects. PPAR Res (2010) 0.84
Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists. PPAR Res (2009) 0.84
Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis. Sci Rep (2016) 0.83
Comparison of TCDD-elicited genome-wide hepatic gene expression in Sprague-Dawley rats and C57BL/6 mice. Toxicol Appl Pharmacol (2012) 0.83
Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism. PPAR Res (2010) 0.81
The Role of PPARs in the Endothelium: Implications for Cancer Therapy. PPAR Res (2008) 0.81
Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta (2016) 0.81
Clustering nuclear receptors in liver regeneration identifies candidate modulators of hepatocyte proliferation and hepatocarcinoma. PLoS One (2014) 0.81
Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer. Adv Pharmacol (2015) 0.80
Med1 subunit of the mediator complex in nuclear receptor-regulated energy metabolism, liver regeneration, and hepatocarcinogenesis. Gene Expr (2014) 0.80
The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol (2015) 0.80
A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice. J Biol Chem (2015) 0.80
PPARalpha- and DEHP-Induced Cancers. PPAR Res (2008) 0.80
Generation and characterization of a humanized PPARδ mouse model. Br J Pharmacol (2011) 0.79
RB tumor suppressive function in response to xenobiotic hepatocarcinogens. Am J Pathol (2014) 0.79
The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes. BMC Cancer (2015) 0.79
PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation. Am J Pathol (2015) 0.78
The interaction between HCV and nuclear receptor-mediated pathways. Pharmacol Ther (2011) 0.78
Exposure to phthalates affects calcium handling and intercellular connectivity of human stem cell-derived cardiomyocytes. PLoS One (2015) 0.78
Mice deficient in glycerol-3-phosphate acyltransferase-1 have a reduced susceptibility to liver cancer. Toxicol Pathol (2012) 0.78
PPARs and Mitochondrial Metabolism: From NAFLD to HCC. PPAR Res (2016) 0.77
Gene-Gene Interactions among Pparα/δ/γ Polymorphisms for Apolipoprotein (Apo) A-I/Apob Ratio in Chinese Han Population. Iran J Public Health (2014) 0.77
A toxicogenomic approach for the prediction of murine hepatocarcinogenesis using ensemble feature selection. PLoS One (2013) 0.77
New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS. Xenobiotica (2009) 0.77
A single amino acid change humanizes long-chain fatty acid binding and activation of mouse peroxisome proliferator-activated receptor α. J Mol Graph Model (2014) 0.77
A Comparative Study of Mouse Hepatic and Intestinal Gene Expression Profiles under PPARα Knockout by Gene Set Enrichment Analysis. PPAR Res (2011) 0.76
Loss of 5-lipoxygenase activity protects mice against paracetamol-induced liver toxicity. Br J Pharmacol (2015) 0.76
PPARs and nonalcoholic fatty liver disease. Biochimie (2016) 0.75
Retinoic Acid-mediated Nuclear Receptor Activation and Hepatocyte Proliferation. J Exp Clin Med (2009) 0.75
Xenotransplantation models to study the effects of toxicants on human fetal tissues. Birth Defects Res B Dev Reprod Toxicol (2014) 0.75
Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from non-parenchymal cells. Am J Physiol Gastrointest Liver Physiol (2017) 0.75
LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). PLoS One (2015) 0.75
Organotypic modeling of human keratinocyte response to peroxisome proliferators. Cells Tissues Organs (2012) 0.75
Connexin-based signaling and drug-induced hepatotoxicity. J Clin Transl Res (2017) 0.75
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab (2008) 1.67
Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes (2011) 1.56
Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.50
Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol (2009) 1.46
Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology (2011) 1.38
Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther (2010) 1.31
Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation (2007) 1.30
Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology (2013) 1.30
Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther (2007) 1.26
Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology (2011) 1.19
Hypoxia-inducible factor-2α activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res (2012) 1.17
Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity. Hepatology (2012) 1.09
Intestinal hypoxia-inducible factor-2alpha (HIF-2alpha) is critical for efficient erythropoiesis. J Biol Chem (2011) 1.03
Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis. Cell Metab (2012) 1.01
Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci (2012) 0.99
Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia. Proc Natl Acad Sci U S A (2013) 0.98
Hypoxia-inducible factor-2α is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer. Carcinogenesis (2012) 0.97
Analysis of the peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) cistrome reveals novel co-regulatory role of ATF4. BMC Genomics (2012) 0.96
Decreased hepcidin expression in murine β-thalassemia is associated with suppression of Bmp/Smad signaling. Blood (2012) 0.93
Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol (2011) 0.92
Hypoxia-inducible factor 1α regulates a SOCS3-STAT3-adiponectin signal transduction pathway in adipocytes. J Biol Chem (2012) 0.92
Identification of novel proteins induced by estradiol, 4-hydroxytamoxifen and acolbifene in T47D breast cancer cells. Steroids (2006) 0.91
Fibrinogen-γ proteolysis and solubility dynamics during apoptotic mouse liver injury: heparin prevents and treats liver damage. Hepatology (2011) 0.90
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos (2008) 0.90
Control of steroid 21-oic acid synthesis by peroxisome proliferator-activated receptor alpha and role of the hypothalamic-pituitary-adrenal axis. J Biol Chem (2009) 0.90
PPARalpha-dependent activation of cell cycle control and DNA repair genes in hepatic nonparenchymal cells. Toxicol Sci (2010) 0.88
Intestinal iron homeostasis and colon tumorigenesis. Nutrients (2013) 0.88
The hypoxia-inducible factor-C/EBPα axis controls ethanol-mediated hepcidin repression. Mol Cell Biol (2012) 0.85
Iron homeostasis in the liver. Compr Physiol (2013) 0.84
Role of PPARα and HNF4α in stress-mediated alterations in lipid homeostasis. PLoS One (2013) 0.82
Loss of von Hippel-Lindau protein (VHL) increases systemic cholesterol levels through targeting hypoxia-inducible factor 2α and regulation of bile acid homeostasis. Mol Cell Biol (2014) 0.79
Hypoxia-inducible factors: a central link between inflammation and cancer. J Clin Invest (2016) 0.78
In vitro organoid culture of primary mouse colon tumors. J Vis Exp (2013) 0.77
Transgenic mouse models for alcohol metabolism, toxicity, and cancer. Adv Exp Med Biol (2015) 0.76
Cholestasis induces reversible accumulation of periplakin in mouse liver. BMC Gastroenterol (2013) 0.75
Molecular Characterization of Hypoxic Alveolar Epithelial Cells After Lung Contusion Indicates an Important Role for HIF-1α. Ann Surg (2016) 0.75